Research programme: insulin mimetics - Merck & Co
Alternative Names: Demethylasterriquinone B1; DMAQ-B1; Insulin mimetics research programme - Merck & CoLatest Information Update: 25 Mar 2010
Price :
$50 *
At a glance
- Originator Merck & Co
- Class Small molecules
- Mechanism of Action Insulin receptor agonists; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Neurological disorders; Obesity; Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 25 Mar 2010 Discontinued - Preclinical for Neurological disorders in United Kingdom (unspecified route)
- 25 Mar 2010 Discontinued - Preclinical for Obesity in USA (unspecified route)
- 25 Mar 2010 Discontinued - Preclinical for Type-1 diabetes mellitus in USA (PO)